Cidofovir

CHEMBL5314375 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

279.2 g/mol

LogP

-3.6

Phase

4

An antiviral nucleotide analog that inhibits viral DNA polymerase, used intravenously for cytomegalovirus (CMV) retinitis in patients with AIDS when other antivirals are contraindicated. Serious nephrotoxicity is the major dose-limiting toxicity, requiring co-administration of probenecid and aggressive intravenous hydration to reduce kidney damage. It is reserved for refractory or intolerant cases due to its toxicity profile.

Peso Molecular

279,1900 g/mol

LogP

-3,60

TPSA

146,00 Å²

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Pain Management Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Chronic Kidney Disease Hypertension Chronic Pain HIV/AIDS Heart Failure

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

Nc1ccn(C[C@@H](CO)OCP(=O)(O)O)c(=O)n1.O.O

InChI

InChI=1S/C8H14N3O6P.2H2O/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16;;/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16);2*1H2/t6-;;/m0../s1

Molecular Formula

C8H14N3O6P

HBD / HBA

4 / 6

Ligações Rotacionáveis

6

Átomos Pesados

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

An antiviral nucleotide analog that inhibits viral DNA polymerase, used intravenously for cytomegalovirus (CMV) retinitis in patients with AIDS when other antivirals are contraindicated. Serious nephrotoxicity is the major dose-limiting toxicity, requiring co-administration of probenecid and aggressive intravenous hydration to reduce kidney damage. It is reserved for refractory or intolerant cases due to its toxicity profile.

Yes, Cidofovir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5314375. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 60613. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Procura informações acessíveis para o paciente?

Cidofovir no PillFYI

Estrutura

Dados Rápidos

Fórmula: C8H14N3O6P
Sinônimos: 1

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.